CRH Medical Corp.

CRH-T

Analysis and Opinions about CRH-T

Signal
Opinion
Expert
HOLD
HOLD
September 18, 2017

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
September 18, 2017

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

DON'T BUY
DON'T BUY
August 23, 2017

It had an amazing run this year. It was a target of some short sellers, and then they missed on some earnings reports. It is the worst for price momentum. It is actually okay on valuation. It has a decent balance sheet. It is volatile and has poor price momentum.

Show full opinionHide full opinion

It had an amazing run this year. It was a target of some short sellers, and then they missed on some earnings reports. It is the worst for price momentum. It is actually okay on valuation. It has a decent balance sheet. It is volatile and has poor price momentum.

WEAK BUY
WEAK BUY
August 22, 2017

It fell apart and is now working itself back. It got destroyed by credibility, short sellers came along and the stock has readjusted. He thinks the worst is over. It has earnings potential.

Show full opinionHide full opinion

It fell apart and is now working itself back. It got destroyed by credibility, short sellers came along and the stock has readjusted. He thinks the worst is over. It has earnings potential.

COMMENT
COMMENT
August 15, 2017

A stock that is extremely popular with medical analysts. There has been a bit of a foul-up in performance and the stock has joined the Bear market. He doesn’t get the sense that it is as good as a lot of analysts seem to believe. You also have the setback of the Obama-care saga in the US.

Show full opinionHide full opinion

A stock that is extremely popular with medical analysts. There has been a bit of a foul-up in performance and the stock has joined the Bear market. He doesn’t get the sense that it is as good as a lot of analysts seem to believe. You also have the setback of the Obama-care saga in the US.

COMMENT
COMMENT
August 2, 2017

Provides anaesthesia services for gastro-intestinal procedures. They operate in the US, and Medicare and Medicaid are evaluating what people can bill for services. The company has said that the net impact will probably result in an 8% decline in revenue and a 16%-18% decline in EBITDA. When the news broke, the shares dropped about 50%-65%, so it is getting to a time where it has probably been a little oversold. This is going to be higher risk, so you need to be able to withstand 5% moves on any given day. They just did another acquisition and there is a hint that they will be doing many more.

Show full opinionHide full opinion

Provides anaesthesia services for gastro-intestinal procedures. They operate in the US, and Medicare and Medicaid are evaluating what people can bill for services. The company has said that the net impact will probably result in an 8% decline in revenue and a 16%-18% decline in EBITDA. When the news broke, the shares dropped about 50%-65%, so it is getting to a time where it has probably been a little oversold. This is going to be higher risk, so you need to be able to withstand 5% moves on any given day. They just did another acquisition and there is a hint that they will be doing many more.

COMMENT
COMMENT
July 26, 2017

This has been hit extremely hard. It trades to a pretty significant multiple and probably got ahead of itself. On the news and speculation that some kind of reimbursement was going to come, the stock sold down. The code changes are not being reimbursed to the same degree. In the past, they’ve been able to use their currency to a certain degree to make acquisitions. They have just secured a bigger line, so it looks like they’ve shored up their business fairly well. Fairly good cash flow. The reimbursement is going to hurt them, and then the private pay insurance, the majority of their business, will end up coming down over time as well. They are going to have to replace the lost revenue with increased business, either organically or by acquisition.

Show full opinionHide full opinion

This has been hit extremely hard. It trades to a pretty significant multiple and probably got ahead of itself. On the news and speculation that some kind of reimbursement was going to come, the stock sold down. The code changes are not being reimbursed to the same degree. In the past, they’ve been able to use their currency to a certain degree to make acquisitions. They have just secured a bigger line, so it looks like they’ve shored up their business fairly well. Fairly good cash flow. The reimbursement is going to hurt them, and then the private pay insurance, the majority of their business, will end up coming down over time as well. They are going to have to replace the lost revenue with increased business, either organically or by acquisition.

COMMENT
COMMENT
July 24, 2017

News items make it difficult for anyone to analyze. They have one of the best returns of capital. The rules have changed. Probably it is okay. Usually the rule changes sound more threatening than they really are.

Show full opinionHide full opinion

News items make it difficult for anyone to analyze. They have one of the best returns of capital. The rules have changed. Probably it is okay. Usually the rule changes sound more threatening than they really are.

WATCH
WATCH
July 17, 2017

He has no price target. It is another great Canadian healthcare stock that got hammered a short while ago. The reason for the most recent decline is that Central Medical Services has changed how they code some services. This company should eventually be at higher prices, but he wants to see the dust settle.

Show full opinionHide full opinion

He has no price target. It is another great Canadian healthcare stock that got hammered a short while ago. The reason for the most recent decline is that Central Medical Services has changed how they code some services. This company should eventually be at higher prices, but he wants to see the dust settle.

HOLD
HOLD
July 13, 2017

An outsourcer in medical clinics where they take a 50% stake in the business. Registered nurses are being paid as full medical doctors. Their profitability could be hit when they are re-rated. The argument goes on. He thinks the short thesis is a little overplayed.

Show full opinionHide full opinion

An outsourcer in medical clinics where they take a 50% stake in the business. Registered nurses are being paid as full medical doctors. Their profitability could be hit when they are re-rated. The argument goes on. He thinks the short thesis is a little overplayed.

COMMENT
COMMENT
July 10, 2017

When a Short report came out, this dropped about 30%. Had sold about half his position in the $11 range to take some risk off the table. The stock is now close to the level, where if it breaches it, he will be selling his position. Believes their business is strong. He likes the company, but is just a little worried about it technically right now. On a P/E ratio, they seem really expensive. They have a nice ROE.

Show full opinionHide full opinion

When a Short report came out, this dropped about 30%. Had sold about half his position in the $11 range to take some risk off the table. The stock is now close to the level, where if it breaches it, he will be selling his position. Believes their business is strong. He likes the company, but is just a little worried about it technically right now. On a P/E ratio, they seem really expensive. They have a nice ROE.

WATCH
WATCH
June 30, 2017

Going ahead 3 or 4 years, he is pretty comfortable that the whole medical space will be higher. We are in a secular bull market with healthcare. It had a big spike down this year, but the range we are in now has provided some support. There was a low of $6.84 in May, but doesn’t think it is going back there. It seems to be basing around $7.23-$7.38. Look for this to break out at around $7.65-$7.73, which will tell him it is really getting some legs. It is probably going to base here for a while.

Show full opinionHide full opinion

Going ahead 3 or 4 years, he is pretty comfortable that the whole medical space will be higher. We are in a secular bull market with healthcare. It had a big spike down this year, but the range we are in now has provided some support. There was a low of $6.84 in May, but doesn’t think it is going back there. It seems to be basing around $7.23-$7.38. Look for this to break out at around $7.65-$7.73, which will tell him it is really getting some legs. It is probably going to base here for a while.

PAST TOP PICK
PAST TOP PICK
June 22, 2017

(Top Pick Jun 30/16, Up 52%) It was almost $12 at one point and was really stretched, then a short report came out, all before he bought it. He likes the business and feels they will continue to do well. They have great cash flow for acquisitions.

Show full opinionHide full opinion

(Top Pick Jun 30/16, Up 52%) It was almost $12 at one point and was really stretched, then a short report came out, all before he bought it. He likes the business and feels they will continue to do well. They have great cash flow for acquisitions.

COMMENT
COMMENT
May 25, 2017

This got up to $11-$12, where he thought it was a little ahead of itself. Markets were jittery and someone came out with a Short report, so a lot of Shorts piled on and the stock came off quite a bit. At the current value of around $8, it looks half decent. He is comfortable with management.

Show full opinionHide full opinion

This got up to $11-$12, where he thought it was a little ahead of itself. Markets were jittery and someone came out with a Short report, so a lot of Shorts piled on and the stock came off quite a bit. At the current value of around $8, it looks half decent. He is comfortable with management.

COMMENT
COMMENT
May 5, 2017

A recent Short report made some interesting points. Although he doesn’t like serial acquisitors, he likes that this company is very focused on what they are doing. When they make an acquisition, they typically get 50%-51% of the business, so they consolidate it. Their revenue numbers are generally growing much faster than their earnings because they have to take out the minority interests. They are recognizing 100% of the revenues, but effectively are only getting 51% of the earnings. That was one of the thrusts of the Short report. The other was that they were being paid to use an MD to administer their deep sedation (used in colonoscopies), but using specially trained professional nurses instead. A decent company, he is just not sold on it yet.

Show full opinionHide full opinion

A recent Short report made some interesting points. Although he doesn’t like serial acquisitors, he likes that this company is very focused on what they are doing. When they make an acquisition, they typically get 50%-51% of the business, so they consolidate it. Their revenue numbers are generally growing much faster than their earnings because they have to take out the minority interests. They are recognizing 100% of the revenues, but effectively are only getting 51% of the earnings. That was one of the thrusts of the Short report. The other was that they were being paid to use an MD to administer their deep sedation (used in colonoscopies), but using specially trained professional nurses instead. A decent company, he is just not sold on it yet.

COMMENT
COMMENT
April 26, 2017

Ranks 222 out of 723 stocks in his model. If putting new money to work, you would typically look for something higher up in the rank. Currently trading at $9.12, and the overall earnings estimates for 2017 is $.28, giving a reasonable PE multiple. ROE of 25% looks attractive. Next year’s earnings growth is expected to be 21%, against a 28 PE, giving a PE to growth next year of 1.3X. It looks a bit expensive.

Show full opinionHide full opinion

Ranks 222 out of 723 stocks in his model. If putting new money to work, you would typically look for something higher up in the rank. Currently trading at $9.12, and the overall earnings estimates for 2017 is $.28, giving a reasonable PE multiple. ROE of 25% looks attractive. Next year’s earnings growth is expected to be 21%, against a 28 PE, giving a PE to growth next year of 1.3X. It looks a bit expensive.

Showing 16 to 30 of 89 entries